Post-COVID Syndrome: An Insight on Its Pathogenesis

Helena C Maltezou, Androula Pavli, Athanasios Tsakris, Helena C Maltezou, Androula Pavli, Athanasios Tsakris

Abstract

Post-COVID syndrome is increasingly recognized as a new clinical entity in the context of SARS-CoV-2 infection. Symptoms persisting for more than three weeks after the diagnosis of COVID-19 characterize the post-COVID syndrome. Its incidence ranges from 10% to 35%, however, rates as high as 85% have been reported among patients with a history of hospitalization. Currently, there is no consensus on the classification of post-COVID syndrome. We reviewed the published information on post-COVID syndrome, putting emphasis on its pathogenesis. The pathogenesis of post-COVID syndrome is multi-factorial and more than one mechanism may be implicated in several clinical manifestations. Prolonged inflammation has a key role in its pathogenesis and may account for some neurological complications, cognitive dysfunction, and several other symptoms. A multisystem inflammatory syndrome in adults (MIS-A) of all ages has been also described recently, similarly to multisystem inflammatory syndrome in children (MIS-C). The post-infectious inflammatory pathogenetic mechanism of MIS-A is supported by the fact that its diagnosis is established through serology in up to one third of cases. Other pathogenetic mechanisms that are implicated in post-COVID syndrome include immune-mediated vascular dysfunction, thromboembolism, and nervous system dysfunction. Although the current data are indicating that the overwhelming majority of patients with post-COVID syndrome have a good prognosis, registries to actively follow them are needed in order to define the full clinical spectrum and its long-term outcome. A consensus-based classification of post-COVID syndrome is essential to guide clinical, diagnostic, and therapeutic management. Further research is also imperative to elucidate the pathogenesis of post-COVID syndrome.

Keywords: COVID-19; SARS-CoV-2; complications; inflammation; long term; pathogenesis; post-infectious.

Conflict of interest statement

There is no conflict of interest to declare.

References

    1. World Health Organization Coronavirus Disease (COVID-19) Situation Reports. [(accessed on 7 May 2021)]; Available online: .
    1. Lagier J.C., Million M., Gautret P., Colson P., Cortaredona S., Giraud-Gatineau A. Outcomes of 3737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. Travel Med. Infect. Dis. 2020;36:101791. doi: 10.1016/j.tmaid.2020.101791.
    1. Eythorsson E., Helgason D., Ingvarsson R.F., Bjornsson H.K., Olafsdottir L.B., Bjarnadottir V. Clinical spectrum of coronavirus disease 2019 in Iceland: Population based cohort study. BMJ. 2020;371:m4529. doi: 10.1136/bmj.m4529.
    1. Maltezou H.C., Raftopoulos V., Vorou R., Papadima K., Mellou K., Spanakis N., Kossyvakis A., Gioula G., Exindari M., Froukala E., et al. Association between upper respiratory tract viral load, comorbidities, disease severity, and outcome of patients with SARS-CoV-2 infection. J. Infect. Dis. 2021;223:1132–1138. doi: 10.1093/infdis/jiaa804.
    1. Pavli A., Theodoridou M., Maltezou H.C. Post-COVID syndrome: Incidence, clinical spectrum, and challenges for primary healthcare professionals. Arch. Med. Res. 2021 doi: 10.1016/j.arcmed.2021.03.010.
    1. Havervall S., Rosell A., Phillipson M., Mangsbo S.M., Nilsson P., Hober S., Thelin C. Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers. JAMA. 2021 doi: 10.1001/jama.2021.5612.
    1. Patient-Led Research Collaborative Report: What Does COVID-19 Recovery Actually Look Like? An Analysis of the Prolonged COVID-19 Symptoms Survey by Patient-Led Research Team. [(accessed on 7 May 2021)]; Available online:
    1. Writing Committee for the COMEBAC Study Group. Morin L., Savale L., Pham T., Colle R., Figueiredo S., Harrois A., Gasnier M., Lecoq A.L., Meyrignac O., et al. Four-month clinical status of cohort of patients after hospitalization for COVID-19. JAMA. 2021 doi: 10.1001/jama.2021.3331.
    1. Alpert O., Begun L., Garren P., Solhkhah R. Cytokine storm induced new onset depression in patients with COVID-19. A new look into the association between depression and cytokines—Two case reports. Brain Behav. Immun. Health. 2020;9:100173. doi: 10.1016/j.bbih.2020.100173.
    1. Dicpinigaitis P.V., Canning B.J. Is there (will there be) a post-COVID-19 chronic cough? Lung. 2020;198:863–865. doi: 10.1007/s00408-020-00406-6.
    1. Koumpa F.S., Forde C.T., Manjaly J.G. Sudden irreversible hearing loss post COVID-19. BMJ Case Rep. 2020;13:e238419. doi: 10.1136/bcr-2020-238419.
    1. Sun B., Tang N., Peluso M.J., Iyer N.S., Torres L., Donatelli J.L., Munter S.E., Nixon C.C., Rutishauser R.L., Rodriguez-Barraquer I., et al. Characterization and biomarker analyses ofpost-COVID-19 complications and neurological manifestations. Cells. 2021;10:386. doi: 10.3390/cells10020386.
    1. Wiersinga W.J., Rhodes A., Cheng A.C., Peacock S.J., Prescott H.C. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA. 2020;324:782–793. doi: 10.1001/jama.2020.12839.
    1. Greenhalgh T., Knight M., A’Court M., Buxton M., Husain L. Management of post-acute COVID-19 in primary care. BMJ. 2020;370:m3026. doi: 10.1136/bmj.m3026.
    1. Tenforde M., Kim S., Lindsell C., Billig Rose E., Shapiro N.I., Files D.C., Gibbs K.W., Erickson H.L., Steingrub J.S., Smithline H.A., et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network-United States, March–June 2020. MMWR Morb. Mortal. Wkly. Rep. 2020;69:993–998. doi: 10.15585/mmwr.mm6930e1.
    1. Covid-19-Long-Term-Health-Effects. [(accessed on 7 May 2021)]; Available online: .
    1. Carvalho-Schneider C., Laurent E., Lemaignen A., Lemaignen A., Beaufils E., Bourbao-Tournois C., Laribi S., Flament T., Ferreira-Maldent N., Bruyère F., et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin. Microbiol. Infect. 2021;27:258–263. doi: 10.1016/j.cmi.2020.09.052.
    1. Becker R.C. COVID-19 and its sequelae: A platform for optimal patient care, discovery and training. J. Thromb. Thrombolysis. 2021:1–8. doi: 10.1007/s11239-021-02375-w.
    1. Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T., et al. Post-acute COVID syndrome. Nat. Med. 2021;27:601–615. doi: 10.1038/s41591-021-01283-z.
    1. Al-Jahdhami I., Al-Naamani K., Al-Mawali A. The post-acute COVID-19 syndrome (long COVID) Oman Med. J. 2021;36:e220. doi: 10.5001/omj.2021.91.
    1. Scordo K.A., Richmond M.M., Munro N. Post-COVID-19 syndrome: Theoretical basis, identification, and management. AACN Adv. Crit. Care. 2021:e1–e8. doi: 10.4037/aacnacc2021492.
    1. Amenta E.M., Spallone A., Rodriguez-Barradas M.C., El Sahly H.M., Atmar R.L., Kulkarni P.A. Post-acute COVID-19: An overview and approach to classification. [(accessed on 7 May 2021)];Open Forum Infect. Dis. 2020 Available online:
    1. Fernandez-de-Las-Penas C., Palacios-Cena D., Gomez-Mayordomo V., Cuadrado M.L., Florencio L.L. Defining post-COVID symptoms (post-acute COVID, long COVID, persistent post-COVID): An integrative classification. Int. J. Environ. Res. Public Health. 2021;18:2621. doi: 10.3390/ijerph18052621.
    1. Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., Kang L., Guo L., Liu M., Zhou X., et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet. 2021;397:220–232. doi: 10.1016/S0140-6736(20)32656-8.
    1. Simani L., Ramezani M., Darazam I.A., Sagharichi M., Aalipour M.A., Ghorbani F., Pakdaman H. Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19. J. Neurovirol. 2021;27:154–159. doi: 10.1007/s13365-021-00949-1.
    1. Carfi A., Bernabei R., Landi R. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603–605. doi: 10.1001/jama.2020.12603.
    1. Addison A.B., Wong B., Ahmed T., Macchi A., Konstantinidis I., Huart C., Frasnelli J., Fjaeldstad A.W., Ramakrishnan V.R., Rombaux P., et al. Clinical olfactory working group consensus statement on the treatment ofpostinfectious olfactory dysfunction. J. Allergy Clin. Immunol. 2021;147:1704–1719. doi: 10.1016/j.jaci.2020.12.641.
    1. Le Bon S.D., Pisarski N., Verbeke J., Prunier L., Cavelier G., Thill M.-P., Rodriguez A., Dequanter D., Lechien J.R., Le Bon O., et al. Psychophysical evaluation of chemosensory functions 5 weeks after olfactory loss due to COVID-19: A prospective cohort study on 72 patients. Eur. Arch. Oto-Rhino-Laryngol. 2020;278:101–108. doi: 10.1007/s00405-020-06267-2.
    1. Moreno-Pérez O., Merino E., Leon-Ramirez J.M., Prunier L., Cavelier G., Thill M.P., Rodriguez A., Dequanter D., Lechien J.R., Le Bon O., et al. COVID19-ALC research Post-acute COVID-19 Syndrome. Incidence and risk factors: A Mediterranean cohort study. J. Infect. 2021;82:378–383. doi: 10.1016/j.jinf.2021.01.004.
    1. Garg P., Arora U., Kumar A., Wig N. The “post-COVID” syndrome: How deep is the damage? J. Med. Virol. 2021;93:673–674. doi: 10.1002/jmv.26465.
    1. Liang L., Yang B., Jiang N., Fu W., He X., Zhou Y., Ma W.L., Wang X. Three-month follow-up study of survivorsof Coronavirus Disease 2019 after discharge. J. Korean Med. Sci. 2020;35:e418. doi: 10.3346/jkms.2020.35.e418.
    1. Moldofsky H., Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC Neurol. 2011;11:37. doi: 10.1186/1471-2377-11-37.
    1. Willi S., Luthold R., Hunt A., Hanggi N.V., Sejdiu D., Scaff C., Bender N., Staub K., Schlagenhauf P. COVID-19 sequelae in adults aged less than 50 years: A systemic review. Travel. Med. Infect. Dis. 2021;40:101995. doi: 10.1016/j.tmaid.2021.101995.
    1. Halpin S.J., McIvor C., Whyatt E.G., Adams A., Harvey O., McLean L., Walshaw C., Kemp S., Corrado J., Singh R., et al. Post-discharge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J. Med. Virol. 2021;93:1013–1022. doi: 10.1002/jmv.26368.
    1. Garrigues E., Janvier P., Kherabi Y., Le Bot A., Hamon A., Gouze H., Doucet L., Berkani S., Oliosi E., Mallart E., et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J. Infect. 2020;81:e4–e6. doi: 10.1016/j.jinf.2020.08.029.
    1. Davis H.E., Assaf G.S., McCorkell L., Wei H., Low R.J., Re’em Y., Redfield S., Austin J.P., Akrami A. Characterizing Long COVID in an International Cohort: 7 Months of Symptoms and Their Impact. [(accessed on 7 May 2021)]; Available online: .
    1. Bellan M., Soddu D., Balbo P.E., Baricich A., Zeppegno P., Avanzi G.C., Baldon G., Bartolomei G., Battaglia M., Battistini S., et al. Respiratory and psychophysical sequelae among patients withCOVID-19four months after hospital discharge. JAMA Netw. Open. 2021;4:e2036142. doi: 10.1001/jamanetworkopen.2020.36142.
    1. Chopra V., Flanders S.A., O’Malley M., Malani A.N., Prescott H.C. Sixty-day outcomes among patients hospitalized with COVID-19. Ann. Intern. Med. 2021;174:576–578. doi: 10.7326/M20-5661.
    1. Saeed S., Tadic M., Larsen T.H., Grassi G., Mancia G. Coronavirus disease 2019 and cardiovascular complications; focused clinical review. J. Hypertens. 2021 doi: 10.1097/HJH.0000000000002819.
    1. Mitrani R.D., Dabas N., Goldberger J.J. COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors. Heart Rhythm. 2020;17:1984–1990. doi: 10.1016/j.hrthm.2020.06.026.
    1. Alemanno F., Houdayer E., Parma A., Spina A., Del Forno A., Scatolini A., Angelone S., Brugliera L., Tettamanti A., Beretta L., et al. COVID-19 cognitive deficits after respiratory assistance in the subacute phase: ACOVID-rehabilitation unit experience. PLoS ONE. 2021;16:e0246590. doi: 10.1371/journal.pone.0246590.
    1. Soloveva N.V., Makarova E.V., Kichuk I.V. Coronavirus syndrome: COVID-19 psychotrauma. Eur. J. Transl. Myol. 2021;30:9302. doi: 10.4081/ejtm.2020.9302.
    1. Chang M.C., Park D. Incidence of post-traumatic stress disorder after Coronavirus Disease. Health Care. 2020;8:373. doi: 10.3390/healthcare8040373.
    1. Raahimi M.M., Kane A., Moore C.E., Alareed A.W. Late onset of Guillain-Barre syndrome following SARS-CoV-2 infection: Part of long COVID-19 syndrome? BMJ Case Rep. 2021;14:e240178. doi: 10.1136/bcr-2020-240178.
    1. Camdessanche J.P., Morel J., Pozzetto B., Paul S., Tholance Y., Botelho-Nevers E. COVID-19 may induce Guillain-Barré syndrome. Rev. Neurol. 2020;176:516–518. doi: 10.1016/j.neurol.2020.04.003.
    1. Emamikhah M., Babadi M., Mehrabani M., Jalili M., Pouranian M., Daraie P., Mohaghegh F., Aghavali S., Zaribafian M., Rohani M. Opsoclonus-myoclonus syndrome, a post-infectious neurologic complication of COVID-19: Case series and review of literature. J. Neurovirol. 2021;27:26–34. doi: 10.1007/s13365-020-00941-1.
    1. Scoppettuolo P., Borrelli S., Naeije G. Neurological involvement in SARS-CoV-2 infection: A clinical systematic review. Brain Behav. Immun. Health. 2020;5:100094. doi: 10.1016/j.bbih.2020.100094.
    1. Shahali H., Ghasemi A., Farahani R.H., Nezami Asl A., Hazrati E. Acute transverse myelitis after SARS-CoV-2 infection: A rare complicated case of rapid onset paraplegia. J. Neurovirol. 2021:1–5. doi: 10.1007/s13365-021-00957-1.
    1. Kilbertus S. Acute transverse myelitis attributed to SARS-CoV-2 infection presenting as impaired mobility: A case report. CJEM. 2021:1–2. doi: 10.1007/s43678-021-00104-z.
    1. Xia X., Wang Y., Zheng J. COVID-19 and Alzheimer’s disease: How one crisis worsens the other. Transl. Neurodegener. 2021;10:15. doi: 10.1186/s40035-021-00237-2.
    1. Leta V., Rodríguez-Violante M., Abundes A., Rukavina K., Teo J.T., Falup-Pecurariu C., Irincu L., Rota S., Bhidayasiri R., Storch A., et al. Parkinson’s disease and post-COVID-19 syndrome: The Parkinson’s long-COVID spectrum. Mov. Disord. 2021 doi: 10.1002/mds.28622.
    1. Dennis A., Wamil M., Alberts J., Oben J., Cuthbertson D.J., Wootton D., Crooks M., Gabbay M., Brady M., Hishmeh L., et al. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: A prospective, community-based study. BMJ Open. 2021;11:e048391.
    1. Gautret P., Million M., Jarrot P.A., Camoin-Jau L., Colson P., Fenollar F., Leone M., La Scola B., Devaux C., Gaubert J.Y., et al. Natural history of COVID-19 and the rapeutic options. Expert Rev. Clin. Immunol. 2020;16:1159–1184. doi: 10.1080/1744666X.2021.1847640.
    1. Trougakos I.P., Stamatelopoulos K., Terpos E., Tsitsilonis O.E., Aivalioti E., Paraskevis D., Kastritis E., Pavlakis G.N., Dimopoulos M.A. Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. J. Biomed Sci. 2021;28:9. doi: 10.1186/s12929-020-00703-5.
    1. Stratton C.W., Tang Y.W., Lu H. Pathogenesis-directed therapy of 2019 novel coronavirus disease. J. Med.Virol. 2021;93:1320–1342. doi: 10.1002/jmv.26610.
    1. Ortelli P., Ferrazzoli D., Sebastianelli L., Engl M., Romanello R., Nardone R., Bonini I., Koch G., Saltuari L., Quartarone A., et al. Neuropsychological and neurophysiological correlates of fatigue in post-acute patients with neurological manifestations of COVID-19: Insights into a challenging symptom. J. Neurol. Sci. 2021;420:117271. doi: 10.1016/j.jns.2020.117271.
    1. Garcia-Oscos F., Salgado H., Hall S., Thomas F., Farmer G.E., Jorge Bermeo J., Galindo L.C., Ramirez R.D., D’Mello S., Rose-John S., et al. The stress-induced cytokine interleukin-6 decreases the inhibition/excitation ratio in the rat temporal cortex via trans-signaling. Biol. Psychiatry. 2012;71:574–582.
    1. Ritchie K., Chan D., Watermeyer T. The cognitive consequences of the COVID-19 epidemic: Collateral damage? Brain Commun. 2020;2:fcaa069. doi: 10.1093/braincomms/fcaa069.
    1. Wostyn P. COVID-19 and chronic fatigue syndrome: Is the worst yet to come? Med. Hypotheses. 2021;146:110469. doi: 10.1016/j.mehy.2020.110469.
    1. Dani M., Dirksen A., Taraborrelli P., Torocastro M., Panagopoulos D., Sutton R., Lim P.B. Autonomic dysfunction in ’long COVID’: Rationale, physiology and management strategies. Clin. Med. 2021;21:e63–e67. doi: 10.7861/clinmed.2020-0896.
    1. Konig M.F., Powell M., Staedtke V., Bai R.Y., Thomas D.L., Fischer N., Hug S., Khalafallah A.M., Koenecke A., Xiong R., et al. Preventing cytokine storm syndrome in COVID-19 using α-1 adenergic receptor antagonists. J.Clin. Investig. 2020;130:3345–3347. doi: 10.1172/JCI139642.
    1. Carroll E., Neumann H., Aguero-Rosenfeld M.E., Lighter J., Czeisler B.M., Melmed K., Lewis A. Post-COVID-19 inflammatory syndrome manifesting as refractory status epilepticus. Epilepsia. 2020;61:e135–e139. doi: 10.1111/epi.16683.
    1. Tale S., Ghosh S., Meitei S.P., Kolli M., Garbhapu A.K., Pudi S. Post-COVID-19 pneumonia pulmonary fibrosis. QJM. 2020;113:837–838. doi: 10.1093/qjmed/hcaa255.
    1. Boumaza A., Gay L., Mezouar S., Bestion E., Diallo A.B., Michel M., Desnues B., Raoult D., La Scola B., Halfon P., et al. Monocytes and macrophages, targets of SARS-CoV-2: The clue for Covid-19 immunoparalysis. J. Infect. Dis. 2021:jiab044. doi: 10.1093/infdis/jiab044.
    1. Muller J.A., Grob R., Conzelmann C., Kruger J., Merle U., Steinhart J., Weil T., Koepke L., PrelliBozzo C., Read C., et al. SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat. Metab. 2021;3:149–165. doi: 10.1038/s42255-021-00347-1.
    1. Hayden M.R. An immediate and long-term complication of COVID-19 may be type 2 diabetes mellitus: The central role of β-cell dysfunction, apoptosis and exploration of possible mechanisms. Cells. 2020;9:2475. doi: 10.3390/cells9112475.
    1. Sathish T., Tapp R.J., Cooper M.E., Zimmer P. Potential metabolic and inflammatory pathways between COVID-19 and new-onset diabetes. Diabetes Metab. 2021;47:101204. doi: 10.1016/j.diabet.2020.10.002.
    1. Abrams J.Y., Godfred-Cato S.E., Oster M.E., Chow E.J., Koumans E.H., Bryant B., Leung J.W., Belay E.D. Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2: A systemic review. J. Pediatr. 2020;226:45–54. doi: 10.1016/j.jpeds.2020.08.003.
    1. Bamrah Morris S., Schwartz N., Patel P., Abbo L., Beauchamps L., Balan S., Lee E.H., Paneth-Pollak R., Geevarughese A., Lash M.K., et al. Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection-United Kingdom and United States, March–August 2020. Morbid/Mortal. Wkly. Rep. 2020;69:1450–1456.
    1. Novak P. Post COVID-19 syndrome associated with orthostatic cerebral hypoperfusion syndrome, small fiber neuropathy and benefit of immunotherapy: A case report. Eneurological Sci. 2020;21:100276. doi: 10.1016/j.ensci.2020.100276.
    1. Nuzzo D., Cambula G., Bacile I., Rizzo M., Galia M., Mangiapane P., Picone P., Giacomazza D., Scalisi L. Long-term brain disorders in post Covid-19 neurological syndrome (PCNS) patient. Brain Sci. 2021;11:454. doi: 10.3390/brainsci11040454.
    1. Nazy I., Jevtic S.D., Moore J.C., Huynh A., Smith J.W., Kelton J.G., Arnold D.M. Platelet-activating immune complexes identified in critically ill COVID-19 patients suspected of heparin-induced thrombocytopenia. J. Thromb. Haemost. 2021;19:1342–1347. doi: 10.1111/jth.15283.
    1. Brodard J., Kremer Hovingam J.A., Fontanam P., Studt J.D., Gruel Y., Greinacher A. COVID-19 patients often show high-titer non-platelet-activating anti-PF4/heparin IgG antibodies. J. Thromb. Haemost. 2021;19:1294–1298. doi: 10.1111/jth.15262.
    1. Kumar M.A., Krishnaswamy M., Arul J.N. Post COVID-19 sequelae: Venous thromboembolism complicated by lower GI bleed. BMJ Case Rep. 2021;14:e241059. doi: 10.1136/bcr-2020-241059.
    1. Townsend L., Fogarty H., Dyer A., Martin-Loeches I., Bannan C., Nadarajan P., Bergin C., O’Farrelly C., Conlon N., Bourke N.M., et al. Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response. J. Thromb. Haemost. 2021;19:1064–1070. doi: 10.1111/jth.15267.
    1. Ladds E., Rushforth A., Wieringa S., Taylor S., Rayner C., Husain L., Greenhalgh T. Persistent symptoms after COVID-19: Qualitative study of 114 “long COVID” patients and draft quality principles for services. BMC Health Serv. Res. 2020;20:1144. doi: 10.1186/s12913-020-06001-y.
    1. Davido B., Seang S., Tubiana R., de Truchis P. Post-COVID-19 chronic symptoms: A postinfectious entity? Clin. Microbiol. Infect. 2020;26:1448–1449. doi: 10.1016/j.cmi.2020.07.028.
    1. Washington Post Some Long-Haul COVID-19 Patients Say Their Symptoms are Subsiding after Getting Vaccines. [(accessed on 7 May 2021)]; Available online: .
    1. Medscape Pediatrics Some with Long COVID See Relief after Vaccination. [(accessed on 7 May 2021)]; Available online: .

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren